Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results -Company on track to submit IND for Phase 2 AML clinical trial in the third quarter, with first patient enrolled by year end- -MultiTAA T cel

Therapeutics Reports First Quarter 2019 Operating and Financial Results

on track to submit IND for Phase 2 AML clinical trial in the third quarter, with first patient enrolled by year end-

T cell therapies continue to generate positive clinical results across various indications in investigator-sponsored trials-

to report update from Phase 1/2 clinical trial in pancreatic cancer in Q3 2019-

TX -May 9th, 2019- Marker Therapeutics, Inc. (NASDAQ:MRKR),

a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the

treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results

for the first quarter ended March 31, 2019.

to make significant progress this quarter. Based on our early interactions with the U.S. FDA, we are confident in our submission

package for our IND for post-transplant acute myeloid leukemia (AML). In light of the feedback from the FDA, we plan to submit

an IND for a Phase 2 clinical trial in the third quarter, which should enable us to enroll the first

patient by the end of the year," said Peter L. Hoang, President & CEO of

Marker Therapeutics. "Depending on the results and upon further discussions with the FDA, we believe that if results

are positive, this has the potential to serve as a pivotal trial-particularly if results are consistent with data generated

to date from our MultiTAA therapies in investigator-sponsored trials. We look forward to initiating our first company-sponsored

trial in such an important disease area, for which there are limited treatment options. Additionally,

we anticipate reporting an update from our solid tumor program in pancreatic cancer in the third quarter."

Targeted (MultiTAA) T Cell Therapies

on interactions with the U.S. Food and Drug Administration (FDA) on the clinical trial design of the planned Marker-sponsored Phase

2 clinical trial in post-transplant AML, the Company remains on track to submit an Investigational New Drug (IND) application in

the third quarter, and anticipates first patient enrolled by the end of 2019. The multicenter trial will evaluate clinical efficacy

of Marker's MultiTAA-specific T cells in patients with AML in both the adjuvant and active disease setting, following an

allogeneic hematopoietic stem cell transplant (HSCT). The dose to be administered in the trial is expected to be the maximum tolerated

dose currently determined in the Baylor College of Medicine-sponsored Phase 1 trial. In the adjuvant setting, patients will be

randomized to either MultiTAA therapy at approximately 90 days post-transplant or standard of care observation, while the active

disease patients will receive MultiTAA T cells as part of a single-arm group at approximately 90 days post-transplant.

In several ongoing investigator-sponsored

Phase 1 clinical trials led by Baylor College of Medicine (BCM), Marker's MultiTAA therapies have demonstrated the potential

to mediate a meaningful anti-tumor effect, as well as significant in vivo expansion of T cells. Across all hematological

indications studied in these trials-including AML, lymphoma, acute lymphoblastic leukemia (ALL), and multiple myeloma-MultiTAA

therapy has appeared to be well-tolerated, with no incidence of cytokine release syndrome, neurotoxicity or any other serious adverse

events related to the therapy.

Marker plans to report additional

interim data from BCM's ongoing Phase 1/2 clinical trial in pancreatic cancer in the third quarter of 2019. The

Phase 1/2 trial is a three-arm trial which includes chemo-responsive patients (Arm A), chemo-refractory patients (Arm B)

and an exploratory arm for patients who have surgically-resectable disease (Arm C). Patients in the chemo-responsive arm have completed

at least three months of standard-of-care chemotherapy, and are receiving up to six administrations of MultiTAA T cells in alternation

with chemotherapy. Patients in the chemo-refractory arm are either ineligible for chemotherapy or have progressed on chemotherapy,

and are receiving up to six doses of MultiTAA T cells as a monotherapy. The surgically-resectable patients are receiving a dose

of T cells prior to surgical resection which allows Marker to assess the tumor samples for T-cell infiltration, epitope spreading

and other important characteristics. These patients are eligible to receive five additional doses of T cells after surgical resection.

T Cell Based Vaccines

January 2019, the Company has completed enrollment in its Phase 2 clinical trial in ovarian cancer using TPIV200 as a maintenance

therapy for patients in their first remission after surgery and platinum-based chemotherapy, with a total of 120 patients enrolled,

randomized, and treated at 17 clinical sites. The trial completed enrollment six months faster than anticipated and the Company

expects to reach its planned interim analysis trigger of 55 patients who have progressed before the end of 2019 and to report the

results of this interim analysis in the fourth quarter of 2019.

Company reported initial findings from its dose-finding, four-arm Phase 2 clinical trial in triple negative breast cancer, including

low- and high-dose TPIV200 with or without cyclophosphamide. Of 27 patients evaluated for immunogenicity, 26 showed significant

immune response to the vaccine treatment. Of 80 patients treated at 11 clinical sites, 14 have shown disease progression, as of

April 30, 2019, following treatment with TPIV200.

loss for the quarter ended March 31,

2019 was $5.3 million compared to a net loss of $3.2 million for the quarter ended March 31, 2018.

and development expenses were $2.8 million for the quarter ended March 31, 2019, an increase of $1.2 million, compared to $1.6

million for the quarter ended March 31, 2018. The increase was primarily attributable to increased headcount-related expenses,

stock-based compensation expenses and consulting expenses resulting from the expansion of our internal infrastructure as we advance

the clinical development of our MultiTAA T cell product candidates.

and administrative expenses were $2.8 million for the quarter ended March 31, 2019, an increase of $1.2 million, compared to $1.6

million for the quarter ended March 31, 2018. The increase was primarily attributable to an increase in general and administrative

headcount and stock-based compensation expenses.

March 31, 2019, Marker had cash and cash equivalents of $57.7 million. The Company believes that its existing cash and cash equivalents

will fund the Company's current operations into late 2020.

UPCOMING NEAR-TERM POTENTIAL MILESTONES

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based

immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology

is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor

targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets

following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity.

Because Marker does not genetically engineer its T cells therapies, we believe that our product candidates will be easier and less

expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide

patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic

product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Marker is also advancing a number of innovative

peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program

(TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase 2 clinical

For additional information, please call

toll free at (904) 862-6490 or visit: markertherapeutics.com

To receive future press releases via email,

please visit: https://markertherapeutics.com/email-alerts/

Forward-Looking Statement Disclaimer

This release contains forward-looking

statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this

news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements

concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking

statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses

or current expectations concerning, among other things: our research and development activities relating to our non-engineered

multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs; the effectiveness of these programs or the

possible range of application and potential curative effects and safety in the treatment of diseases; and, the timing and success

of our clinical trials, as well as clinical trials conducted by our collaborators. Forward-looking statements are by their nature

subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such

statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most

recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation

to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of

Marker Therapeutics, Inc.

Consolidated Balance Sheets

Marker Therapeutics, Inc.

Consolidated Statements of Operations